// App-Quantinova.ai

5058 : Impact of previous abiraterone acetate treatment in docetaxel safety profile: Preliminary results of the randomized phase II ABIDO-SOGUG trial.

Researchers

Presenter

  • Ignacio Duran

Principal Investigators

  • Albert Font

  • M Isabel Saez

  • Daniel E. Castellano

  • Maria Jose Mendez-Vidal

  • Javier Puente

  • Carmen Santander

  • Jose Angel Arranz Arija

  • Enrique Grande

  • Martin Lazaro Quintela

  • Alfredo Sanchez-Hernandez

  • Aranzazu Gonzalez del Alba

  • Javier Cassinello

  • Pablo Maroto

  • Emilio Esteban

  • Begona Perez-Valderrama

  • Maria Jose Juan Fita

  • Olatz Etxaniz

  • Begona Mellado

Medical Centers

  • Hospital Universitario Virgen del Rocio, Sevilla, Spain

  • Instiuto Valenciano de Oncologia, Valencia, Spain

  • Institut Catala d'Oncologia, Hospital Universitario German Trias i Pujol, Badalona, Spain

  • CNIO-IBIMA Genitorurinary Cancer Clinical Research Unit, Hospitales Universitarios Virgen de la Victoria & Regional de Malaga, Malaga, Spain

  • Hospital Universitario Doce de Octubre, Madrid, Spain

  • Hospital Universitario Reina Sofia, Cordoba, Spain

  • Hospital Clinico Universitario San Carlos, Madrid, Spain

  • H. Universitario Miguel Servet, Zaragoza, Spain

  • Hospital Universitario Quiron Madrid, Madrid, Spain

  • Medical Oncology Department. Hospital Universitario La Paz, Madrid, Spain

  • Complejo Hospital Universitario de Vigo, Vigo, Spain

  • Hospital Provincial Castellon, Castellon, Spain

  • Hospital Universitario Son Espases, Palma de Mallorca, Spain

  • General Hospital, Guadalajara, Spain

  • Hospital Santa Creu i Sant Pau, Barcelona, Spain

  • Hospital Universitario Central de Asturias, Oviedo, Spain

  • Medical Oncology Department. Hospital Universitario Virgen del Rocio, Seville, Spain

  • Instiuto Valenciano de Oncologia, Valencia, Spain

  • Medical Oncology Department. Catalan Institute of Oncology, Hospital Germans Trias i Pujol, Badalona, Spain

  • Medical Oncology, Hospital Clinic de Barcelona, Barcelona, Spain

Locations

  • Spain

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Metastatic castration-resistant prostate cancer

Biomarkers

  • N/A

Drug/Treatment

  • CB-7598

  • Docetaxel

Outcome

  • Unknown

Study Design

  • Randomized

Phase

  • II

Study Id's

  • NCT02036060

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved